Exchange: NASDAQ·Updated 07:30 PM EDT

LGND Earnings

Latest Earnings Results: Q2 '26

Reported: Aug 06

Estimated EPS

$1.95

Reported EPS

$2.37

Surprise

+21.48%

Estimated Rev

$60.87M

Reported Rev

$63.69M

Surprise

+4.64%

• Reported GAAP EPS of $2.42 up 868.00% YoY • Reported revenue of $63.69M up 33.73% YoY • Ligand Pharmaceuticals is reaffirming its 2026 full-year revenue guidance and is raising the low end of its adjusted earnings per diluted share guidance range to approximately $9.00 to $9.50.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Investor Presentation10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '26
$2.30
--
--
N/A
Q2 '26
$1.95
$2.37
21.48%
BEAT
Q1 '26
$1.82
$1.63
-10.23%
MISSED
Q4 '25
$1.50
$2.02
34.92%
BEAT
Q3 '25
$1.93
$3.09
60.24%
BEAT

Advertisement|Remove ads.